Tscan therapeutics reports fourth quarter and full year 2023 financial results and provides business update

Presented updated data from ongoing phase 1 study of tsc-100 and tsc-101 for the treatment of heme malignancies at the tandem meetings of astct and cibmtr; 8/8 (100%) patients in treatment arms are relapse-free and show complete donor chimerism
TCRX Ratings Summary
TCRX Quant Ranking